製品: Cytochrome P450 7A1 Antibody
カタログ: DF2612
タンパク質の説明: Rabbit polyclonal antibody to Cytochrome P450 7A1
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat
予測: Pig, Horse, Rabbit, Dog
分子量: 58 kDa; 58kD(Calculated).
ユニプロット: P22680
RRID: AB_2839818

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(88%), Horse(88%), Rabbit(100%), Dog(100%)
クローナリティ:
Polyclonal
特異性:
Cytochrome P450 7A1 Antibody detects endogenous levels of total Cytochrome P450 7A1.
RRID:
AB_2839818
引用形式: Affinity Biosciences Cat# DF2612, RRID:AB_2839818.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

Cholesterol 7 alpha hydroxylase; Cholesterol 7 alpha monooxygenase; Cholesterol 7-alpha-hydroxylase; Cholesterol 7-alpha-monooxygenase; CP7A; CP7A1_HUMAN; CYP 7; CYP7; CYP7A1; CYPVII; Cytochrome P450 7A1; Cytochrome P450, family 7, subfamily A, polypeptide 1; Cytochrome P450, subfamily VIIA (cholesterol 7 alpha monooxygenase),; Cytochrome P450, subfamily VIIA (cholesterol 7 alpha-monooxygenase), polypeptide 1; MGC126826; MGC138389;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
発現特異性:
P22680 CP7A1_HUMAN:

Detected in liver.

タンパク質の説明:
Catalyzes a rate-limiting step in cholesterol catabolism and bile acid biosynthesis by introducing a hydrophilic moiety at position 7 of cholesterol. Important for cholesterol homeostasis.
タンパク質配列:
MMTTSLIWGIAIAACCCLWLILGIRRRQTGEPPLENGLIPYLGCALQFGANPLEFLRANQRKHGHVFTCKLMGKYVHFITNPLSYHKVLCHGKYFDWKKFHFATSAKAFGHRSIDPMDGNTTENINDTFIKTLQGHALNSLTESMMENLQRIMRPPVSSNSKTAAWVTEGMYSFCYRVMFEAGYLTIFGRDLTRRDTQKAHILNNLDNFKQFDKVFPALVAGLPIHMFRTAHNAREKLAESLRHENLQKRESISELISLRMFLNDTLSTFDDLEKAKTHLVVLWASQANTIPATFWSLFQMIRNPEAMKAATEEVKRTLENAGQKVSLEGNPICLSQAELNDLPVLDSIIKESLRLSSASLNIRTAKEDFTLHLEDGSYNIRKDDIIALYPQLMHLDPEIYPDPLTFKYDRYLDENGKTKTTFYCNGLKLKYYYMPFGSGATICPGRLFAIHEIKQFLILMLSYFELELIEGQAKCPPLDQSRAGLGILPPLNDIEFKYKFKHL

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
100
Dog
100
Pig
88
Horse
88
Sheep
75
Chicken
75
Bovine
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P22680 基板として

Site PTM Type Enzyme
T4 Phosphorylation
Y176 Phosphorylation
T266 Phosphorylation
S268 Phosphorylation
T269 Phosphorylation
Y432 Phosphorylation
Y433 Phosphorylation
S439 Phosphorylation

研究背景

機能:

A cytochrome P450 monooxygenase involved in the metabolism of endogenous cholesterol and its oxygenated derivatives (oxysterols). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Functions as a critical regulatory enzyme of bile acid biosynthesis and cholesterol homeostasis. Catalyzes the hydroxylation of carbon hydrogen bond at 7-alpha position of cholesterol, a rate-limiting step in cholesterol catabolism and bile acid biosynthesis. 7-alpha hydroxylates several oxysterols, including 4beta-hydroxycholesterol and 24-hydroxycholesterol. Catalyzes the oxidation of the 7,8 double bond of 7-dehydrocholesterol and lathosterol with direct and predominant formation of the 7-keto derivatives.

細胞の位置付け:

Endoplasmic reticulum membrane>Single-pass membrane protein. Microsome membrane>Single-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Detected in liver.

タンパク質ファミリー:

Belongs to the cytochrome P450 family.

研究領域

· Metabolism > Lipid metabolism > Primary bile acid biosynthesis.

· Metabolism > Lipid metabolism > Steroid hormone biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Digestive system > Cholesterol metabolism.

参考文献

1). Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis. PHYTOMEDICINE, 2022 (PubMed: 35605478) [IF=7.9]

2). NRF2 and FXR dual signaling pathways cooperatively regulate the effects of oleanolic acid on cholestatic liver injury. Phytomedicine, 2023 (PubMed: 36343550) [IF=7.9]

3). Targeting mTOR/YY1 signaling pathway by quercetin through CYP7A1-mediated cholesterol-to-bile acids conversion alleviated type 2 diabetes mellitus induced hepatic lipid accumulation. Phytomedicine, 2023 (PubMed: 36889164) [IF=7.9]

4). The protective effect of forsythiaside A on 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestatic liver injury in mice: Based on targeted metabolomics and molecular biology technology. Biochimica et biophysica acta. Molecular basis of disease, 2023 (PubMed: 37523877) [IF=6.2]

5). Antarctic krill peptide alleviated liver fibrosis via downregulating secondary bile acid activated NLRP3 signaling pathway. Food & Function, 2022 (PubMed: 35762853) [IF=6.1]

6). Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury. Life sciences, 2024 (PubMed: 38104861) [IF=6.1]

7). miR-182-5p promotes hepatocyte-stellate cell crosstalk to facilitate liver regeneration. Communications Biology, 2022 (PubMed: 35915318) [IF=5.9]

Application: WB    Species: Mouse    Sample: liver

Fig. 7 Hepatic miR-182-5p targets Cyp7a1 to promote hepatocyte proliferation. a The heatmap of DEGs in BA synthesis signaling pathway. Green represents downregulation while red represents up regulation. qRT-PCR analyses of Cyp7a1 and Cyp27a1 gene expression in the liver of miR-182-5p KO (b) or TG mice (c) compared with their respective control mice (3d after PH; n = 4/group). miR-182-5p mimic (182 m) or its negative control (ncm) were overexpressed in primary hepatocytes from C57BL/6 J mice. d, e miR-182-5p level, and the Cyp7a1 and Cyp27a1 genes expression levels were determined by qRT-PCR (n = 5/group). f The Cyp7a1 protein expression level was determined by western blot. g Alignment of the sequences of Cyp7a1 gene promoter and miR-182-5p. h Luciferase reporter assay to examine the interactions between miR-182-5p and the predicted target site in the Cyp7a1 gene promoter. Plasmids with the Cyp7a1 gene promoter or mutated gene promoter were co-transfected with miR-182-5p mimic or control mimic into primary hepatocytes. Renilla luciferase activity was measured by a Dual-Glo luciferase assay system and normalized to internal control firefly luciferase activity (n = 3 biological Replicates). HSCs co-cultured with Cyp7a1 siRNA (HepCyp7a1-siRNA) or their control siRNA-treated (HepNC-siRNA) hepatocytes isolated from TG mice. i, j qRT-PCR analyses of α-SMA and Ihh genes expression in HSCs. k qRT-PCR analyses of Cyclin genes expression in primary hepatocytes. l EdU immunostaining of primary hepatocytes. m A proposed model on the mechanism by which miR-182-5p regulates liver regeneration induced by PH. Error bars in all experiments represent SEM; Significance was determined by unpaired two-tailed Student’s t test and by one-way ANOVA.

8). Polygoni Multiflori Radix interferes with bile acid metabolism homeostasis by inhibiting Fxr transcription, leading to cholestasis. Frontiers in pharmacology, 2023 (PubMed: 36950015) [IF=5.6]

9). Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway. Frontiers in Pharmacology, 2022 (PubMed: 36278226) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 6 EPC ameliorated MAFLD formation in rats by regulating BA metabolism. (A–G) Relative expression of CYP7A1, FXR, CYP27A1, BSEP, CYP7B1, CYP8B1, NTCP mRNA in liver, n = 6; (H–L) Relative expression of protein CYP7A1, FXR, SHP, p-AMPK, and p-ERK in the liver, n = 4; (M–N) Relative expression of protein FXR and FGF15 in the ileum, n = 4. (O–P) Representative immunoblotting images of CYP7A1, FXR, SHP, p-AMPK,and p-ERK in the liver. (Q) Representative immunoblotting images of FXR and FGF15 in the ileum. Data are presented as mean ± SEM. One-way analysis of variance (ANOVA) was conducted for the group comparison. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MOD group. CYP7A1, cholesterol 7α-hydroxylase; FXR, farnesoid X receptor; CYP27A1, sterol 27-hydroxylase; BSEP, bile salt export protein; CYP7B1, oxysterol 7α-hydroxylase; CYP8B1, sterol 12αhydroxylase; NTCP, Na + -taurocholate co-transporting polypeptides; SHP, small heterodimer partner; AMPK, 5’-AMP-activated protein kinase; ERK, Extracellular signal-regulated kinase.

10). Lycium barbarum L. Balanced intestinal flora with YAP1/FXR activation in drug-induced liver injury. International immunopharmacology, 2024 (PubMed: 38428146) [IF=5.6]

もっと読みます

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.